Speaker illustration

Associate Professor Marco Canepa

University of Genova, Genoa (Italy)

Member of:

Heart Failure Association

Professor Marco Canepa took is MD degree in 2006 at the University of Genova, Italy, where he also obtained his fellowship in Cardiology and PhD degree. In late 2010 he moved to Baltimore, MD, USA, where he worked as Research Fellow at the NIA/NIH under the supervision of Dr. Lakatta and Ferrucci, and joined the HCM Clinic of the Johns Hopkins Medical School held by Dr. Abraham. In 2013 he was appointed Assistant Professor in Cardiology at the University of Genova, and in 2020 Associate Professor. He is currently co-head of the HF and head of the HCM Outpatient Clinics at the San Martino Hospital. His main research interests are heart failure and hypertrophic cardiomyopathies. He has ongoing collaborations with national and international research groups. He is fellow of the HFA, member of the Editorial Board of the IJC and JCM, active reviewer for renowned cardiovascular journals, and author of more than 50 publications on peer-review journals, in most of which he is first author.

Prognostic impact of ICD interventions in a real-world primary and secondary prevention population

Event: Heart Failure 2019

Topic: Implantable Cardioverter-Defibrillator (ICD)

Session: Rapid Fire 6 - Risk stratification and prognosis


Clinical characteristics of heart failure patients admitted to internal medicine vs. cardiology units: the VASCO study

Event: Heart Failure 2019

Topic: Epidemiology, Prognosis, Outcome

Session: Chronic Heart Failure – Epidemiology, Prognosis, Outcome


Heart therapy: benefits and risks for the lung

Event: Heart Failure 2018

Topic: Chronic Heart Failure, Other

Session: Cardiopulmonary interactions: an update for a clinician


Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure. Data from the GISSI-Heart Failure trial.


Topic: The lungs (COPD)

Session: Moderated Poster Session 6 - Comorbidities


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb